Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.

Maximilian Johannes Steinhardt,Xiang Zhou,Franziska Krummenast,Katharina Meckel,Katharina Nickel,David Böckle,Janin Messerschmidt,Sebastian Knorz,Alexander Dierks,Anke Heidemeier,Constantin Lapa,Hermann Einsele,Leo Rasche,Klaus Martin Kortüm

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.

2020

Maximilian Johannes Steinhardt
Xiang Zhou
Franziska Krummenast
Katharina Meckel
Katharina Nickel
David Böckle
Janin Messerschmidt
Sebastian Knorz
Alexander Dierks
Anke Heidemeier
Constantin Lapa
Hermann Einsele
Leo Rasche
Klaus Martin Kortüm

We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem a...

Keywords:

Bortezomib
Internal medicine
Salvage therapy
Proteasome inhibitor
Minimal residual disease
Daratumumab
Progression-free survival
Oncology
Pomalidomide
Multiple myeloma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations